Why Is Sharp Rise Expected in Teleradiology Market Size post Pandemic? The teleradiology market is expected to grow at a 15.2% CAGR in the span of 2021–2030, from $7,145.0 million in 2021 to $25,631.2 million by 2030. This will be because of a sharp increase in the volume of advanced imaging procedures worldwide. With the disease prevalence increasing day by day, there is an acute shortage of experienced radiologists. As per the stats of the Association of American Medical Colleges, there will be a shortage of around 122,000 medics in 2032. As per the report of the WHO, globally, there are around 3,600 million radiological tests performed worldwide on an annual basis. The rate at which the radiological examination volume is rising will turn out to be an important factor for the growth of the teleradiology market in the coming years. Apart from this, the risk of cardiovascular diseases and cancer is on the rise, thus giving a boom to the market, since CT and MRI scans are widely conducted to diagnose them and during treatment. There was a positive impact on this industry during the pandemic, with a prolific rise in the number of CT scans and chest X-rays. With a rapid growth in the number of teleradiology tests, North America’s revenue share was the largest, at 50%, in 2021. Till now, the confirmed COVID-19 cases in the U.S. are 79,716,910, and a total of 979,321 deaths have been reported. This is the reason the popularity of the teleradiology concept was increasing by leaps and bounds and will continue to do so in the future also. The scope of the teleradiology market will be better in the coming years as there is a prediction of a further rise in the demand for radio imaging. The use of artificial intelligence in this regard will facilitate teleradiology providers across the globe. This is because it can lessen the reading time and even ensure pinpoint accuracy. Stroke, which has emerged as one of the most-potent health scares, can be diagnosed by doctors in no time using AI-integrated radiology, which can help reduce the chance of death. The hardware and software market is expected to show rapid growth, much faster than the service market, in the coming years. This is why every possible effort is being made by IT professionals to improve the operability and technical aspects of teleradiology. One of the foremost reasons for the growth of the teleradiology market is that most of the hospitals are making use of these systems in order to improve healthcare efficiency during the COVID-19 outbreak. The market was dominated by cardiology applications, with 20% revenue, in 2021, mainly because of an increase in the incidence of cardiovascular diseases (CVDs). There are approximately 18 million deaths because of CVDs every year, says the WHO. Out of the total deaths from CVDs, roughly 85% are due to strokes and heart attacks. Additionally, in the U.S., one person dies of a CVD every 36 seconds. It is principally why the U.S. has been a prime contributor to the revenue of the teleradiology market in the recent past. Therefore, with the increase in the number of CVD cases, the demand for teleradiology solutions is experiencing a boom. Read More: https://www.psmarketresearch.com/market-analysis/teleradiology-market

North America Led the Contrast Media Market The contrast media market will reach USD 7,647.7 million by 2030, powering at a rate of 4.9% by the end of this decade. There is a considerable growth in the occurrence of chronic circumstances recently as a result of the ever more inactive routines of people. Furthermore, there has been significant consumption of high-calorie foods and prevalence of insufficient physical activity, which are contributing to the expansion of chronic disorders. Industry players have a lot of chances attributable to the rising R&D activities in new contrast agents and the conception of fresher applications for them. Based on modality, the X-ray/CT had the largest share, about 50%, in 2022. This is majorly credited to the increase in the occurrence of communicable and non-infectious ailments in the recent past. As per a study, there has been a substantial increase in the volume of CT scans throughout the pandemic. Furthermore, ultrasound will have a substantial share as well. This is due to the fact that contrast sonograms have key compensations over other imaging modalities. They are done without ionizing radiation and are affordable, better, faster, safer, and more suitable than other kinds of diagnostic imaging. Based on product type, the iodinated category dominated the contrast media market, with about 60%, in 2022, because of the growing use of X-ray and CT. Moreover, unchanging, nonionic iodinated compounds are available for improved diagnoses, which contributes substantially to the expansion of the industry. Based on application, cardiovascular ailments had the major share, about 40%, in 2022, because of the increasing count of elder people. According to a study by the WHO, the major reason of death worldwide is CVD, which is responsible for taking up 17.9 million lives on a yearly basis. Additionally, the rate at which the aging population is rising is significantly higher than in the past. North America dominated the industry with a share of about 45%, in 2022. The inpatient examinations count is increasing as a result of the reputable healthcare amenities, inclusive disease screening programs introduced by, state, federal, and provincial governments, easy access to pioneering tech, and increasing requirement for improved management of the prevailing diseases. Also, the occurrence of the key players is a bulging contributing factor to the expansion of the industry. Europe will hold a key share, mainly credited to the substantial geriatric populace. Since elder people are susceptible to chronic ailments, the demand for effective detection techs escalates. Furthermore, the robust economy, which leads to the facility of eminence healthcare services, is a main contributor. It is because of the growing requirement for progressive contrast agents, the requirement for contrast media solutions will continue to grow in the years to come. Read More: https://www.psmarketresearch.com/market-analysis/contrast-media-market

Artificial Intelligence (AI) Infrastructure Market Opportunities and Forecast By 2029 The persuasive Artificial Intelligence (AI) Infrastructure market research report makes available fluctuations in CAGR values during the forecast period of 2021-2028 for the market. This wide ranging market study also analyzes the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis. The competitive landscape section of the report emphasizes on understandable insight about the market share analysis of major industry players. The report offers all-encompassing study about production capacity, consumption, import and export for all the major regions across the world. What is more, businesses can gain insights into profit growth and sustainability programme with an influential Artificial Intelligence (AI) Infrastructure market report. Global Artificial Intelligence (AI) Infrastructure Market was valued at USD 23.50 billion in 2021 and is expected to reach USD 422.55 billion by 2029, registering a CAGR of 43.50% during the forecast period of 2022-2029. Cloud account for the largest deployment type segment in the respective market owing to the increase in the number of data center providers and cloud companies. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, import/export analysis, pricing analysis, production consumption analysis, and pestle analysis. Browse Full Report Along With Facts and Figures @ https://www.databridgemarketresearch.com/reports/global-ai-infrastructure-market Market Overview: An Artificial Intelligence (AI) infrastructure refers to the technology that assists with machine learning (ML). The technology signifies the combination of machine learning and artificial intelligence solutions for development and deployment of scalable, reliable and specific data solutions. AI Infrastructure is known to key enable the whole machine learning process from start to finish. COVID-19 Impact on Artificial Intelligence (AI) Infrastructure Market The COVID-19 pandemic had a positive impact on the artificial intelligence (AI) infrastructure market. It helped millions of people globally in leveraging advanced tools for various applications, especially healthcare. Artificial intelligence (AI) infrastructure was highly useful for numerous medical applications such as decoding genomic sequence for drug development, enhancement of CT scans, remote patient monitoring, and healthcare chatbots, among others. The artificial intelligence (AI) infrastructure market is expected to witness high growth Post-COVID-19 due to the adoption of smart manufacturing processes using AI, blockchain and IoT technologies. Recent Developments Intel announced to launch a 3rd Gen Intel Xeon Scalable processor in April’2021. The processor provides a balanced architecture with built-in artificial intelligence, advanced security capabilities and crypto acceleration. AMD announced the news regarding acquisition of Xilinx in April’2021. The acquisition will offer both companies complementary product portfolios and assist in capitalizing opportunities in the industry. Some of the major players operating in artificial intelligence (AI) infrastructure market are · Cisco (US) · IBM (US) · Intel Corporation (US) · SAMSUNG (South Korea) · Google (US) · Microsoft (US) · Micron Technology, Inc (US) · NVIDIA Corporation (US) · Oracle (US) · Arm Limited (UK) · Xilinx (US) · Advanced Micro Devices, Inc (US) Browse Trending Reports: https://www.databridgemarketresearch.com/reports/global-marketing-attribution-software-market https://www.databridgemarketresearch.com/reports/global-service-integration-and-management-market https://www.databridgemarketresearch.com/reports/global-finance-cloud-market https://www.databridgemarketresearch.com/reports/global-artificial-intelligence-ai-platform-service-market https://www.databridgemarketresearch.com/reports/global-e-discovery-market https://www.databridgemarketresearch.com/reports/global-emotion-detection-recognition-market About Data Bridge Market Research: An absolute way to predict what the future holds is to understand the current trend! Data Bridge Market Research presented itself as an unconventional and neoteric market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are committed to uncovering the best market opportunities and nurturing effective information for your business to thrive in the marketplace. Data Bridge strives to provide appropriate solutions to complex business challenges and initiates an effortless decision-making process. Data Bridge is a set of pure wisdom and experience that was formulated and framed in 2015 in Pune. Data Bridge Market Research has more than 500 analysts working in different industries. We have served more than 40% of the Fortune 500 companies globally and have a network of more than 5,000 clients worldwide. Data Bridge is an expert in creating satisfied customers who trust our services and trust our hard work with certainty. We are pleased with our glorious 99.9% customer satisfaction rating. Contact Us: - Data Bridge Market Research US: +1 888 387 2818 United Kingdom: +44 208 089 1725 Hong Kong: +852 8192 7475 Email: – corporatesales@databridgemarketresearch.com

Global Focus on Improved Outcomes: Global Pulmonary Fibrosis Biomarker Market The global Pulmonary Fibrosis Biomarkers Market is set to experience significant growth over the next decade, driven by advancements in medical research and an increasing focus on early diagnosis and treatment of pulmonary fibrosis. In 2023, the market was valued at USD 4,149.0 million and is projected to reach USD 4,353.0 million by 2024. This upward trajectory is expected to continue, with sales accelerating at a compound annual growth rate (CAGR) of 4.4% from 2024 to 2034, ultimately reaching USD 6,538.4 million by 2034. Pulmonary fibrosis is a serious condition that affects lung function, and early detection through reliable biomarkers is crucial for effective management and treatment. The growing prevalence of this condition, along with technological advancements in biomarker research, is fueling the market’s expansion. Request Your Detailed Report Sample With Your Work Email: https://www.futuremarketinsights.com/reports/sample/rep-gb-17615 The projected growth of the pulmonary fibrosis biomarker market underscores the evolving landscape of pulmonary fibrosis research and clinical practice. As the prevalence of pulmonary fibrosis continues to rise, fueled by factors such as aging populations and environmental exposures, the demand for reliable biomarkers is expected to grow correspondingly. In order to provide clinicians with the ability to evaluate medication efficacy, make necessary treatment adjustments, and follow the course of the disease over time, pulmonary fibrosis biomarkers are essential for tracking disease activity and treatment response. Sustained observation is essential for assessing the effectiveness of treatment and improving patient care. Key Takeaways: Accelerated Growth: Sales of pulmonary fibrosis biomarkers are projected to accelerate at a CAGR of 4.4% from 2024 to 2034, indicating robust market expansion. Market Projection: The market is expected to increase from US$ 4,353.0 million in 2024 to US$ 6,538.4 million by 2034, reflecting growing demand and advancements in biomarker technologies. Critical Role: Pulmonary fibrosis biomarkers play a vital role in the diagnosis, prognosis, and treatment monitoring of pulmonary fibrosis, contributing to improved patient outcomes and quality of life. Competitive Landscape: Key pulmonary fibrosis biomarker manufacturers significantly shape the sector’s competitive landscape. Known for its dedication to innovation, Biogen welcomes Veracyte, which is one of the significant pulmonary fibrosis biomarker providers, emphasizing cutting-edge diagnostic solutions. Galapagos NV offers its advantages to the market, while Genentech, a Roche company, adds its pharmaceutical knowledge. Biocartis and Myriad Genetics are essential in pulmonary fibrosis biomarkers since they offer specific solutions. These key pulmonary fibrosis biomarker vendors work together to enhance research and development, which supports the market’s general expansion and development for pulmonary fibrosis biomarkers. Their combined efforts highlight the pulmonary fibrosis biomarker industry’s dynamic nature as it continues to tackle the difficulties related to pulmonary fibrosis. Latest Advancements: To provide Oklahomans with the newest diagnostic and therapeutic equipment, O.U. Health, a comprehensive academic health system, and Siemens Healthineers, a leader in medical technology, announced a strategic 10-year value partnership in December 2023. Thermo Fisher Scientific and AstraZeneca collaborated in January 2023 to create a companion diagnostic test for Tagrisso based on solid tissue and blood. With its global presence, Thermo Fisher Scientific can service a wide range of clients and take advantage of expansion prospects worldwide. A deal to buy all of the outstanding shares of Curiosity Diagnostics from Scope Fluidics, S.A., was announced by Bio-Rad Laboratories, Inc. in August 2022. The deal could be worth up to US$ 170 million, with roughly US$ 100 million going toward cash and another US$ 70 million coming from future milestone payments. Biogen Inc. agreed to pay a total of US$ 900 million in September 2022 to settle allegations that it gave doctors payments to persuade them to prescribe Biogen drugs, which resulted in the doctors making false claims with Medicare and Medicaid. Key Players: Biogen Veracyte Genentech (Roche) Galapagos NV Biocartis Myriad Genetics Key Developments in the Pulmonary Fibrosis Biomarkers Market: In September 2022, Biogen Inc. has consented to pay a total of US$ 900 million to resolve claim that it paid kickbacks to doctors to encourage them to prescribe Biogen medications, which led to the filing of false claims with Medicare and Medicaid. Segmentation Analysis of the Pulmonary Fibrosis Biomarkers Market: By Test Type: HRCT Scans X-Ray Scans Lung Biopsy Blood Tests Pulmonary Function Tests By End User: Diagnostic Laboratories Academic and Research Institutes Hospital Laboratories Biopharmaceutical Companies Others By Region: North America Latin America Europe East Asia South Asia Oceania The Middle East & Africa